BPMC Quote, Financials, Valuation and Earnings

PTC Therapeutics has a net margin of -43.9% compared to Blueprint Medicines's net margin of -54.2%. Blueprint Medicines's return on equity of -50.13% beat PTC Therapeutics's return on equity of --.

Blueprint Medicines has a consensus price target of $125.58, signalling upside risk potential of 39.24%. On the other hand PTC Therapeutics has an analysts' consensus of -- which suggests that it could grow by 26.98%. Given that Blueprint Medicines has higher upside potential than PTC Therapeutics, analysts believe Blueprint Medicines is more attractive than PTC Therapeutics.

Blueprint Medicines has a beta of 0.586, which suggesting that the stock is 41.419% less volatile than S&P 500. In comparison PTC Therapeutics has a beta of 0.629, suggesting its less volatile than the S&P 500 by 37.101%.

Blueprint Medicines has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PTC Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Blueprint Medicines pays -- of its earnings as a dividend. PTC Therapeutics pays out -- of its earnings as a dividend.

Blueprint Medicines quarterly revenues are $128.2M, which are smaller than PTC Therapeutics quarterly revenues of $196.8M. Blueprint Medicines's net income of -$56.3M is higher than PTC Therapeutics's net income of -$106.7M. Notably, Blueprint Medicines's price-to-earnings ratio is -- while PTC Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Blueprint Medicines is 13.02x versus 3.92x for PTC Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of -43.9% compared to Blueprint Medicines's net margin of 36.03%. Blueprint Medicines's return on equity of -50.13% beat Regeneron Pharmaceuticals's return on equity of 17.19%.

Blueprint Medicines has a consensus price target of $125.58, signalling upside risk potential of 39.24%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $1,053.08 which suggests that it could grow by 50.04%. Given that Regeneron Pharmaceuticals has higher upside potential than Blueprint Medicines, analysts believe Regeneron Pharmaceuticals is more attractive than Blueprint Medicines.

Blueprint Medicines has a beta of 0.586, which suggesting that the stock is 41.419% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.084, suggesting its less volatile than the S&P 500 by 91.622%.

Blueprint Medicines has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Blueprint Medicines pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

Blueprint Medicines quarterly revenues are $128.2M, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3.7B. Blueprint Medicines's net income of -$56.3M is lower than Regeneron Pharmaceuticals's net income of $1.3B. Notably, Blueprint Medicines's price-to-earnings ratio is -- while Regeneron Pharmaceuticals's PE ratio is 17.37x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Blueprint Medicines is 13.02x versus 5.83x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

SpringWorks Therapeutics has a net margin of -43.9% compared to Blueprint Medicines's net margin of -108.58%. Blueprint Medicines's return on equity of -50.13% beat SpringWorks Therapeutics's return on equity of -51.38%.

Blueprint Medicines has a consensus price target of $125.58, signalling upside risk potential of 39.24%. On the other hand SpringWorks Therapeutics has an analysts' consensus of -- which suggests that it could grow by 91.2%. Given that SpringWorks Therapeutics has higher upside potential than Blueprint Medicines, analysts believe SpringWorks Therapeutics is more attractive than Blueprint Medicines.

Blueprint Medicines has a beta of 0.586, which suggesting that the stock is 41.419% less volatile than S&P 500. In comparison SpringWorks Therapeutics has a beta of 0.862, suggesting its less volatile than the S&P 500 by 13.8%.

Blueprint Medicines has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SpringWorks Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Blueprint Medicines pays -- of its earnings as a dividend. SpringWorks Therapeutics pays out -- of its earnings as a dividend.

Blueprint Medicines quarterly revenues are $128.2M, which are larger than SpringWorks Therapeutics quarterly revenues of $49.3M. Blueprint Medicines's net income of -$56.3M is lower than SpringWorks Therapeutics's net income of -$53.5M. Notably, Blueprint Medicines's price-to-earnings ratio is -- while SpringWorks Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Blueprint Medicines is 13.02x versus 18.90x for SpringWorks Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals has a net margin of -43.9% compared to Blueprint Medicines's net margin of 37.71%. Blueprint Medicines's return on equity of -50.13% beat Vertex Pharmaceuticals's return on equity of -2.89%.

Blueprint Medicines has a consensus price target of $125.58, signalling upside risk potential of 39.24%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $498.24 which suggests that it could grow by 25.42%. Given that Blueprint Medicines has higher upside potential than Vertex Pharmaceuticals, analysts believe Blueprint Medicines is more attractive than Vertex Pharmaceuticals.

Blueprint Medicines has a beta of 0.586, which suggesting that the stock is 41.419% less volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.364, suggesting its less volatile than the S&P 500 by 63.631%.

Blueprint Medicines has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Blueprint Medicines pays -- of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend.

Blueprint Medicines quarterly revenues are $128.2M, which are smaller than Vertex Pharmaceuticals quarterly revenues of $2.8B. Blueprint Medicines's net income of -$56.3M is lower than Vertex Pharmaceuticals's net income of $1B. Notably, Blueprint Medicines's price-to-earnings ratio is -- while Vertex Pharmaceuticals's PE ratio is 25.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Blueprint Medicines is 13.02x versus 9.73x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.